Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Denifanstat - Sagimet Biosciences

Drug Profile

Denifanstat - Sagimet Biosciences

Alternative Names: [14C]-TVB-2640; ASC 40; TVB-2640

Latest Information Update: 09 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator 3-V Biosciences
  • Developer Ascletis; Mayo Clinic; Sagimet Biosciences; University of Kentucky; University of Texas Health Science Center at San Antonio
  • Class Antiacnes; Antineoplastics; Benzonitrile; Cyclobutanes; Hepatoprotectants; Piperidines; Skin disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Fatty acid synthetase complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acne vulgaris; Glioblastoma
  • Phase II Astrocytoma; Breast cancer; Non-alcoholic steatohepatitis; Non-small cell lung cancer
  • Phase I Liver disorders; Prostate cancer
  • Preclinical Liver cancer
  • No development reported Colorectal cancer; Solid tumours

Most Recent Events

  • 06 May 2024 Sagimet Biosciences plans a phase III trial for Nonalcoholic Fatty Liver Disease with related fibrosis in second half of 2024
  • 30 Apr 2024 Preclinical trials in Liver cancer in USA (PO), prior to April 2024 (Sagimet Biosciences pipeline, April 2024)
  • 25 Mar 2024 Sagimet Biosciences expects an end of phase II meeting with US FDA in Non-alcoholic steatohepatitis in first half of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top